Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
- PMID: 26063472
- PMCID: PMC4561509
- DOI: 10.1016/S0140-6736(15)60692-4
Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013
Abstract
Background: Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for 188 countries between 1990 and 2013.
Methods: Estimates were calculated for disease and injury incidence, prevalence, and YLDs using GBD 2010 methods with some important refinements. Results for incidence of acute disorders and prevalence of chronic disorders are new additions to the analysis. Key improvements include expansion to the cause and sequelae list, updated systematic reviews, use of detailed injury codes, improvements to the Bayesian meta-regression method (DisMod-MR), and use of severity splits for various causes. An index of data representativeness, showing data availability, was calculated for each cause and impairment during three periods globally and at the country level for 2013. In total, 35 620 distinct sources of data were used and documented to calculated estimates for 301 diseases and injuries and 2337 sequelae. The comorbidity simulation provides estimates for the number of sequelae, concurrently, by individuals by country, year, age, and sex. Disability weights were updated with the addition of new population-based survey data from four countries.
Findings: Disease and injury were highly prevalent; only a small fraction of individuals had no sequelae. Comorbidity rose substantially with age and in absolute terms from 1990 to 2013. Incidence of acute sequelae were predominantly infectious diseases and short-term injuries, with over 2 billion cases of upper respiratory infections and diarrhoeal disease episodes in 2013, with the notable exception of tooth pain due to permanent caries with more than 200 million incident cases in 2013. Conversely, leading chronic sequelae were largely attributable to non-communicable diseases, with prevalence estimates for asymptomatic permanent caries and tension-type headache of 2·4 billion and 1·6 billion, respectively. The distribution of the number of sequelae in populations varied widely across regions, with an expected relation between age and disease prevalence. YLDs for both sexes increased from 537·6 million in 1990 to 764·8 million in 2013 due to population growth and ageing, whereas the age-standardised rate decreased little from 114·87 per 1000 people to 110·31 per 1000 people between 1990 and 2013. Leading causes of YLDs included low back pain and major depressive disorder among the top ten causes of YLDs in every country. YLD rates per person, by major cause groups, indicated the main drivers of increases were due to musculoskeletal, mental, and substance use disorders, neurological disorders, and chronic respiratory diseases; however HIV/AIDS was a notable driver of increasing YLDs in sub-Saharan Africa. Also, the proportion of disability-adjusted life years due to YLDs increased globally from 21·1% in 1990 to 31·2% in 2013.
Interpretation: Ageing of the world's population is leading to a substantial increase in the numbers of individuals with sequelae of diseases and injuries. Rates of YLDs are declining much more slowly than mortality rates. The non-fatal dimensions of disease and injury will require more and more attention from health systems. The transition to non-fatal outcomes as the dominant source of burden of disease is occurring rapidly outside of sub-Saharan Africa. Our results can guide future health initiatives through examination of epidemiological trends and a better understanding of variation across countries.
Funding: Bill & Melinda Gates Foundation.
Copyright © 2015 Elsevier Ltd. All rights reserved.
Figures
![Figure 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4561509/bin/emss-64121-f0001.gif)
![Figure 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4561509/bin/emss-64121-f0002.gif)
![Figure 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4561509/bin/emss-64121-f0003.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4561509/bin/emss-64121-f0004.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4561509/bin/emss-64121-f0004.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4561509/bin/emss-64121-f0004.gif)
![Figure 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4561509/bin/emss-64121-f0004.gif)
![Figure 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/4561509/bin/emss-64121-f0008.gif)
Comment in
-
Transitioning health systems for multimorbidity.Lancet. 2015 Aug 22;386(9995):721-2. doi: 10.1016/S0140-6736(14)62254-6. Epub 2015 Jun 7. Lancet. 2015. PMID: 26063473 No abstract available.
-
Epidemiology: Global Burden of Disease Study 2013 reports that disability caused by CKD is increasing worldwide.Nat Rev Nephrol. 2015 Aug;11(8):446. doi: 10.1038/nrneph.2015.98. Epub 2015 Jun 23. Nat Rev Nephrol. 2015. PMID: 26100503 No abstract available.
Similar articles
-
Global, regional, and national incidence, prevalence, and years lived with disability for 354 diseases and injuries for 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.Lancet. 2018 Nov 10;392(10159):1789-1858. doi: 10.1016/S0140-6736(18)32279-7. Epub 2018 Nov 8. Lancet. 2018. PMID: 30496104 Free PMC article.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016.Lancet. 2017 Sep 16;390(10100):1211-1259. doi: 10.1016/S0140-6736(17)32154-2. Lancet. 2017. PMID: 28919117 Free PMC article.
-
Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.Lancet. 2016 Oct 8;388(10053):1545-1602. doi: 10.1016/S0140-6736(16)31678-6. Lancet. 2016. PMID: 27733282 Free PMC article.
-
Global burden of disease attributable to mental and substance use disorders: findings from the Global Burden of Disease Study 2010.Lancet. 2013 Nov 9;382(9904):1575-86. doi: 10.1016/S0140-6736(13)61611-6. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993280 Review.
-
Global burden of disease attributable to illicit drug use and dependence: findings from the Global Burden of Disease Study 2010.Lancet. 2013 Nov 9;382(9904):1564-74. doi: 10.1016/S0140-6736(13)61530-5. Epub 2013 Aug 29. Lancet. 2013. PMID: 23993281 Review.
Cited by
-
Engineered extracellular vesicle-delivered TGF-β inhibitor for attenuating osteoarthritis by targeting subchondral bone.J Tissue Eng. 2024 Jul 24;15:20417314241257781. doi: 10.1177/20417314241257781. eCollection 2024 Jan-Dec. J Tissue Eng. 2024. PMID: 39071897 Free PMC article.
-
Is anxiety a public health problem among older adults in India: Results from a systematic review and meta-analysis.J Family Med Prim Care. 2024 Jul;13(7):2545-2554. doi: 10.4103/jfmpc.jfmpc_1664_23. Epub 2024 Jun 28. J Family Med Prim Care. 2024. PMID: 39071033 Free PMC article. Review.
-
Prevalence and clinical correlates of abnormal lipid metabolism in older Chinese patients with first-episode drug-naïve major depressive disorder.BMC Psychiatry. 2024 Jul 25;24(1):534. doi: 10.1186/s12888-024-05967-x. BMC Psychiatry. 2024. PMID: 39054520 Free PMC article.
-
Prevalence and determinants of depression among patients with Type 2 diabetes mellitus attending family medicine clinics in Qatar.Am J Med Open. 2022 May 29;9:100014. doi: 10.1016/j.ajmo.2022.100014. eCollection 2023 Jun. Am J Med Open. 2022. PMID: 39035064 Free PMC article.
-
Reversion of chronic to episodic migraine in working age and botulinum toxin-resistant patients treated with fremanezumab: A real-life study.Brain Behav. 2024 Jul;14(7):e3631. doi: 10.1002/brb3.3631. Brain Behav. 2024. PMID: 39034358 Free PMC article.
References
-
- Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG. The epidemiology and global burden of autism spectrum disorders. Psychol Med. 2014;45:1–13. - PubMed
-
- Boyers LN, Karimkhani C, Hilton J, Richheimer W, Dellavalle RP. Global Burden of Eye and Vision Disease as Reflected in the Cochrane Database of Systematic Reviews. JAMA Ophthalmol. 2014 published online Sept 18. DOI:10.1001/jamaophthalmol.2014.3527. - PubMed
-
- Charlson FJ, Ferrari AJ, Flaxman AD, Whiteford HA. The epidemiological modelling of dysthymia: application for the Global Burden of Disease Study 2010. J Affect Disord. 2013;151:111–20. - PubMed
Publication types
MeSH terms
Grants and funding
- R01 TW009237/TW/FIC NIH HHS/United States
- 091758/WT_/Wellcome Trust/United Kingdom
- BB/L018926/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- MR/L003120/1/MRC_/Medical Research Council/United Kingdom
- CDF-2013-06-012/DH_/Department of Health/United Kingdom
- UL1 TR001079/TR/NCATS NIH HHS/United States
- 100715/WT_/Wellcome Trust/United Kingdom
- 095066/WT_/Wellcome Trust/United Kingdom
- BB/L018845/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- MR/K006525/1/MRC_/Medical Research Council/United Kingdom
- BB/L017679/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- T32 HD057822/HD/NICHD NIH HHS/United States
- ImNIH/Intramural NIH HHS/United States
- WT_/Wellcome Trust/United Kingdom
- 089963/WT_/Wellcome Trust/United Kingdom
- KL2 TR001088/TR/NCATS NIH HHS/United States
- 089963/Z/09/Z/WT_/Wellcome Trust/United Kingdom
- RG/08/014/24067/BHF_/British Heart Foundation/United Kingdom
- BB/L018926/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- R01 DA003574/DA/NIDA NIH HHS/United States
- UL1 TR001425/TR/NCATS NIH HHS/United States
- BB/L018845/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
- 099876/WT_/Wellcome Trust/United Kingdom
- 5T32HD057822/HD/NICHD NIH HHS/United States
- RP-PG-0407-10184/DH_/Department of Health/United Kingdom
- BB/J010367/1/BB_/Biotechnology and Biological Sciences Research Council/United Kingdom
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical